Novo Nordisk presented preliminary results of its new anti-obesity drug, a weight loss pill that appears to be more effective than the two treatments already marketed by the pharmaceutical company.
- Novo Nordisk presented phase 1 results of a clinical trial of its new weight loss drug, amycretin.
- This allowed participants to lose 13% of their body weight in three months.
- Those who took a placebo lost only 1% of their body weight over the same period.
A new weight loss drug, amycretin, helps you lose 13% of your body weight in three months, according to researchers. phase 1 results of a clinical trial presented by Novo Nordisk. Among the sixteen participants, some received a placebo and only lost 1% of their body weight during these twelve weeks.
A new weight loss drug that is more effective and less restrictive
This new treatment would be twice as effective as the two previous weight loss drugs marketed by the pharmaceutical laboratory: Wegovy and Ozempic. In fact, during previous clinical trials, they only allowed a weight loss of 6% over three months.
A more effective pill therefore, and less restrictive. Wegovy and Ozempic require a weekly injection while the amycretin tested in this clinical trial is taken orally. But it could also be available as injections. During 2025, the results of a clinical trial on this other form should be published.
Amycretin to fight obesity
Like other weight loss drugs, amycretin mimics the intestinal hormone GLP-1, which reduces the appetite. But the difference is that this treatment also mimics another hunger hormone called Amylinwhich could explain its greater effectiveness.
Before marketing, additional studies must be conducted to ensure the safety of this new treatment. In addition, for the moment, amycretin has not been compared to other weight loss treatments within the same clinical trial.
This type of weight loss medication is eagerly awaited because obesity is on the rise. According to a communicated published by the World Health Organization (WHO) on March 1, one in eight people in the world is obese, or more than a billion people.
“Globally, obesity has more than doubled since 1990 among adults, and quadrupled among children and adolescents (aged 5 to 19).”, we can read in the document, which is based on a study published in the journal The Lancet.
But the problem with these weight loss drugs is that patients often gain weight back when they stop taking them. A challenge to be taken up by laboratories for global health.
